Trending/Sean Dowdy

Mayo Clinic: Ovarian Cancer Subtypes May Predict Response to Bevacizumab
CHICAGO — Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has…
Special Topics
Sign up

Mayo Clinic Connect
An online patient support community